The involuntary entrepreneur chemist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Fredrik Lehmann, Venture Partner at Industrifonden. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Fredrik, covering: How the closing of a business and customer requests led to a phoenix from the flames start-up opportunity His company's journey from inception and growth to eventual sale to Recipharm His transition to becoming a VC investor with an evergreen fund within the Nordic life science ecosystem, including the subjectivity of most investments The sentiment Fredrik is seeing from the biotech market and his frustrations of not being able to make more investments in breakthrough science and tech Fredrik focuses on life science with an extra eye for innovative biotechs. He is interested in contributing to businesses with his experience in the biotech world to help companies reach their highest potential. Fredrik has over 20 years of experience in the life science industry as CEO, Head of Research, and CMC in several companies. He has extensive experience in turning ideas into products and successful businesses and has founded six companies, including OnTarget Chemistry, which was acquired by Recipharm in 2015. He also serves as a board director at several Life Sciences companies and is a member of the Scientific Advisory Board at Akthelia Pharmaceuticals. Fredrik holds a PhD in medicinal chemistry from Gothenburg University and an MBA from Stockholm School of Economics. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.